Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Clinical Efficacy and Safety of Recombinant Humanized Anti-CD25 Monoclonal Antibody in Preventing Graft-versus-host Disease After Haploidentical / Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial

NCT06657391 is registered in ClinicalTrials.gov with Rongrong Liu as lead sponsor.

NCT NCT06657391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06657391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Clinical Efficacy and Safety of Recombinant Humanized Anti-CD25 Monoclonal Antibody in Preventing Graft-versus-host Disease After Haploidentical / Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial
Lead sponsor
Rongrong Liu
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2024
Completion date
September 30, 2027
Enrollment
396 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

transfusion dependent thalassemia